Carteyva is a next-generation CD19 CAR T cell therapy approved in China for the treatment of large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. Developed and enhanced from Juno Therapeutics’ pioneering CAR-T technology platform, Carteyva offers durable remission with a safer profile—delivering fewer and milder side effects compared to earlier treatments.
Exclusively available in China, this state-of-the-art therapy is also offered at an accessible and affordable cost.
For more information on how to access Carteyva treatment, please contact us at info@cartcellschina.com.
A patient with high-risk POD24 follicular lymphoma achieved durable complete remission after treatment with Carteuva CD19 CAR-T therapy. This case highlights the growing role of CAR-T therapy in patients with early relapse and limited treatment options.
New Phase II data from China demonstrate that relma-cel CAR-T therapy delivers high response rates and durable survival in heavily pretreated relapsed/refractory mantle cell lymphoma patients.
Alan from the Phillippines sharing his experience of getting CAR-T cell therapy at our affiliated medical center.
China’s domestically developed CAR-T therapy, Carteyva, is giving new hope to patients with relapsed/refractory lymphoma. From a personalized treatment process to promising survival data, this breakthrough cell therapy is reshaping the future of cancer care in China.
Relma-cel CAR-T therapy achieved complete remission in a high-risk, elderly R/R DLBCL patient, offering new hope where standard treatments failed.
In this video, we share the courageous journey of a patient diagnosed with mantle cell lymphoma (MCL), a rare and aggressive type of non-Hodgkin lymphoma. After undergoing multiple rounds of
Discover how CARTEYVA, a CD19-directed CAR-T therapy is advancing treatment for follicular lymphoma with promising results and local availability in China.
NMPA granted Breakthrough Therapy Designation for Carteyva (relmacabtagene autoleucel injection) as second-line treatment in adults with relapsed or refractory large B-cell lymphoma (r/r LBCL) .
A 57 yo high risk MCL achieved CR for two years after treatment with Carveyta, a innovative CAR T-cell therapy recently received
The China NMPA has approved new indication, mantel cell lymphoma (MCL), to Carteyva (Relma-cel), this is the third indication approved for this innovative CAR T-cell therapy.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.